Circulating blood platelets are specialized cells that prevent bleeding and minimize blood
vessel injury. Large progenitor cells in the bone marrow called megakaryocytes (MKs) are …

Pluripotent stem cells (PSCs) hold great promise for drug discovery and regenerative
medicine owing to their ability to differentiate into any cell type in the body. After more than …

The donor-dependent supply of platelets is frequently insufficient to meet transfusion needs.
To address this issue, we developed a clinically applicable strategy for the derivation of …

The production of megakaryocytes (MKs)—the precursors of blood platelets—from human
pluripotent stem cells (hPSCs) offers exciting clinical opportunities for transfusion medicine …

Human induced pluripotent stem cells (iPSCs) provide a potentially replenishable source for
the production of transfusable platelets. Here, we describe a method to generate …

Abstract Platelet transfusions total> 2.17 million apheresis-equivalent units per year in the
United States and are derived entirely from human donors, despite clinically significant …

Mesenchymal stem cells (MSCs) are being tested in a wide range of human diseases;
however, loss of potency and inconsistent quality severely limit their use. To overcome these …

Background—Platelet activation at sites of vascular injury is essential for hemostasis, but it is
also a major pathomechanism underlying ischemic injury. Because anti-inflammatory …

Hematopoietic stem cell transplantation (HSCT) is the first field where human stem cell
therapy was successful. Flooding interest on human stem cell therapy to cure previously …

Generating human hematopoietic stem cells (HSCs) from autologous tissues, when coupled
with genome editing technologies, is a promising approach for cellular transplantation …